Pulling SEC filings + quote and writing the call…
ABUS
Arbutus Biopharma Corp
Next earnings Aug 4, 2026 · consensus $-0.03 EPS, $459K rev
Last earnings +0.0% on 2026-05-13
$4.63
▲ +1.76%$4.55▲ +27.09%
over 1Y
L $3.09EODHDH $4.95
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+1.8%
1W+6.1%
1M+8.3%
3M+4.1%
YTD-4.6%
1Y+27.1%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Buy
Revenue grew 128.2% YoY; but unprofitable (net margin -237.9%).
Arbutus Biopharma Corp shows $14.1M in FY2025 revenue (+128.2% YoY), a -237.9% net margin, and -43.7% ROE.
Sources: SEC EDGAR (CIK 0001447028, latest 10-Q filed 2026-05-13) · EODHD · as of 6/22/2026, 1:52:18 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.